Oncology

Overview

The Oncology research area is composed by nine groups addressing the principal unsolved issues in cancer. Their research covers fields such as child and adolescent cancer, melanoma, Gynecology, Urology, cancer stem cells and the molecular mechanisms of the tumor pathologies.

There are also three groups from the CIBBIM-Nanomedicine. These groups study the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics.

Publications

125

total

725.353

impact factor

5.803

average impact factor

Group Leader: Juan Angel Recio Conde

team

zoom

download

The research interest of the group is focused on the molecular basis of skin cancer progression and treatment. Our research contributed with novel discoveries on skin tumors developed in patients harboring a rare disease named Epidermolysis Bullosa. We genetically defined these tumors and managed to developed a unique PDXs from these tumors, that have attracted collaborations world-wide to study this rare disease. Additionally, we have contributed to the discovery of a novel molecule involve in cell survival and chemoresistance of cancer stem cells, promoting the generation of novel therapeutic molecules against cancer and other diseases. We also participated in a study that contributed to clarify the evolutionary origin of papillary and anaplastic thyroid cancers that will help to stratify patients for treatment.

Following our research in melanoma, we have opened two new projects dedicated to find new treatments for melanoma including subtypes lacking a first line of treatment.

10

total

59^.004

impact factor

5^.900

average impact factor

SELECTED ARTICLES

TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.

Puig I, Tenbaum SP, Chicote I, Arqués O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratù G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P, Seoane J, Recio JA, Vivancos A, Dienstmann R, Tabernero J, Palmer HG. J Clin Invest. 2018 Aug 31;128(9):3887-3905.

doi: 10.1172/JCI96393. Epub 2018 Aug 6.

IF: 14.434

Early evolutionary divergence between papillary and anaplastic thyroid cancers.

Capdevila J, Mayor R, Mancuso FM, Iglesias C, Caratù G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez V, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J. Ann Oncol.

2018 Jun 1;29(6):1454-1460.

doi: 10.1093/annonc/mdy123

IF: 13.9.

Genetic Profiles of Squamous Cell Carcinomas Associated with Recessive Dystrophic Epidermolysis Bullosa Unveil NOTCH and TP53 Mutations and an Increased MYC Expression.

Sans-DeSanNicolas L, Caratú G, Vidal-Cortés O, Sanchez-Redondo S, Ferrer B, Mancuso F, González-Sanchez E, Pérez-Alea M, McGrail K, Hernandez-Losa J, Bodet D, Vivancos A, Garcia-Patos V, Recio JA. J Invest Dermatol. 2018 Jun;138(6):1423-1427.

doi: 10.1016/j.jid.2017.12.026.

Epub 2017 Dec 29

IF: 6.29

The Polycomb proteins RING1B and EZH2 repress the tumoral pro-inflammatory function in metastasizing primary cutaneous squamous cell carcinoma.

Hernández-Ruiz E, Toll A, García-Diez I, Andrades E, Ferrandiz-Pulido C, Masferrer E, Yébenes M, Jaka A, Gimeno J, Gimeno R, García-Patos V, Pujol RM, Hernández-Muñoz I.

Carcinogenesis. 2018 Mar 8;39(3):503-513. doi: 10.1093/carcin/bgz054

IF: 5.232

Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis.

Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, Balada E, Martínez MA, Milisenda JC, Aparicio-Español G, Labrador-Horrillo M, Garcia-Patos V, Grau-Junyent JM, Selva-O’Callaghan A. Rheumatology (Oxford). 2018 Feb 1;57(2):388-396.

doi: 10.1093/rheumatology/kex413.

IF: 5.05

View all publications

Oncology

Overview

Publications

Group Leader: Juan Angel Recio Conde

Research Areas